汗腺膿瘍(Hidradenitis Suppurativa):治療薬開発パイプライン動向(世界、2015年上半期版)

◆英語タイトル:Hidradenitis Suppurativa - Pipeline Review, H1 2015
◆商品コード:GMDHC6218IDB
◆発行会社(調査会社):Global Markets Direct
◆発行日:2015年1月30日
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における汗腺膿瘍(Hidradenitis Suppurativa)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・汗腺膿瘍(Hidradenitis Suppurativa)の概要
・汗腺膿瘍(Hidradenitis Suppurativa)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・汗腺膿瘍(Hidradenitis Suppurativa)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・汗腺膿瘍(Hidradenitis Suppurativa)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・汗腺膿瘍(Hidradenitis Suppurativa)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Hidradenitis Suppurativa – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Hidradenitis Suppurativa – Pipeline Review, H1 2015’, provides an overview of the Hidradenitis Suppurativa’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hidradenitis Suppurativa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hidradenitis Suppurativa and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hidradenitis Suppurativa and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hidradenitis Suppurativa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hidradenitis Suppurativa pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hidradenitis Suppurativa
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hidradenitis Suppurativa pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hidradenitis Suppurativa Overview 6
Therapeutics Development 7
Pipeline Products for Hidradenitis Suppurativa – Overview 7
Pipeline Products for Hidradenitis Suppurativa – Comparative Analysis 8
Hidradenitis Suppurativa – Therapeutics under Development by Companies 9
Hidradenitis Suppurativa – Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Hidradenitis Suppurativa – Products under Development by Companies 13
Hidradenitis Suppurativa – Companies Involved in Therapeutics Development 14
AbbVie Inc. 14
Delenex Therapeutics AG 15
Johnson & Johnson 16
Hidradenitis Suppurativa – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
adalimumab – Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
adalimumab biosimilar – Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
DLX-105 – Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
DLX-2751 – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
ustekinumab – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Hidradenitis Suppurativa – Recent Pipeline Updates 35
Hidradenitis Suppurativa – Dormant Projects 44
Hidradenitis Suppurativa – Discontinued Products 45
Hidradenitis Suppurativa – Product Development Milestones 46
Featured News & Press Releases 46
Oct 13, 2014: AbbVie Announces Late-Breaking Results from Phase 3 Trial of HUMIRA (adalimumab) in Hidradenitis Suppurativa (HS) Patients at the European Academy of Dermatology and Venereology Congress 46
Sep 11, 2014: AbbVie Announces Pivotal Phase 3 Data Evaluating Efficacy of HUMIRA® (adalimumab) in Patients with Hidradenitis Suppurativa (HS), a Chronic Inflammatory Skin Disease 47
Sep 11, 2014: Delenex Announces New Clinical Data 48
Oct 03, 2013: AbbVie Presents Phase II Data Evaluating the Efficacy of HUMIRA in Patients with Hidradenitis Suppurativa 49
Mar 15, 2012: Abbott Announces Patient Enrollment In Two Phase III Studies Of HUMIRA For Moderate To Severe Hidradenitis Suppurativa 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

[List of Tables]
Number of Products under Development for Hidradenitis Suppurativa, H1 2015 7
Number of Products under Development for Hidradenitis Suppurativa - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Late Stage Development, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Hidradenitis Suppurativa - Pipeline by AbbVie Inc., H1 2015 14
Hidradenitis Suppurativa - Pipeline by Delenex Therapeutics AG, H1 2015 15
Hidradenitis Suppurativa - Pipeline by Johnson & Johnson, H1 2015 16
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Stage and Target, H1 2015 19
Number of Products by Stage and Mechanism of Action, H1 2015 21
Number of Products by Stage and Route of Administration, H1 2015 23
Number of Products by Stage and Molecule Type, H1 2015 25
Hidradenitis Suppurativa Therapeutics - Recent Pipeline Updates, H1 2015 35
Hidradenitis Suppurativa - Dormant Projects, H1 2015 44
Hidradenitis Suppurativa - Discontinued Products, H1 2015 45

[List of Figures]
Number of Products under Development for Hidradenitis Suppurativa, H1 2015 7
Number of Products under Development for Hidradenitis Suppurativa - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Assessment by Monotherapy Products, H1 2015 17
Number of Products by Top 10 Targets, H1 2015 18
Number of Products by Stage and Top 10 Targets, H1 2015 19
Number of Products by Top 10 Mechanism of Actions, H1 2015 20
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 21
Number of Products by Top 10 Routes of Administration, H1 2015 22
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 22
Number of Products by Top 10 Molecule Types, H1 2015 24
Number of Products by Stage and Top 10 Molecule Types, H1 2015 25

【掲載企業】

AbbVie Inc.
Delenex Therapeutics AG
Johnson & Johnson

★調査レポート[汗腺膿瘍(Hidradenitis Suppurativa):治療薬開発パイプライン動向(世界、2015年上半期版)] (コード:GMDHC6218IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[汗腺膿瘍(Hidradenitis Suppurativa):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆